Corinne Johnson
Stock Analyst at Goldman Sachs
(3.37)
# 1,011
Out of 5,090 analysts
15
Total ratings
53.85%
Success rate
21.37%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corinne Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MBX MBX Biosciences | Initiates: Sell | $18 | $31.97 | -43.70% | 1 | Dec 4, 2025 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $10 → $20 | $14.20 | +40.85% | 2 | Sep 16, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $20 → $24 | $20.32 | +18.11% | 2 | Sep 5, 2025 | |
| RNA Avidity Biosciences | Reinstates: Buy | $55 | $71.63 | -23.22% | 2 | Jul 10, 2025 | |
| AVBP ArriVent BioPharma | Reinstates: Buy | $33 | $24.69 | +33.66% | 3 | Jul 10, 2025 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $182 | $155.51 | +17.03% | 1 | Jul 10, 2025 | |
| CGON CG Oncology | Upgrades: Buy | $43 → $50 | $43.30 | +15.47% | 3 | May 14, 2024 | |
| IMVT Immunovant | Initiates: Buy | $50 | $22.84 | +118.91% | 1 | Mar 13, 2024 |
MBX Biosciences
Dec 4, 2025
Initiates: Sell
Price Target: $18
Current: $31.97
Upside: -43.70%
Amylyx Pharmaceuticals
Sep 16, 2025
Maintains: Buy
Price Target: $10 → $20
Current: $14.20
Upside: +40.85%
Syndax Pharmaceuticals
Sep 5, 2025
Maintains: Buy
Price Target: $20 → $24
Current: $20.32
Upside: +18.11%
Avidity Biosciences
Jul 10, 2025
Reinstates: Buy
Price Target: $55
Current: $71.63
Upside: -23.22%
ArriVent BioPharma
Jul 10, 2025
Reinstates: Buy
Price Target: $33
Current: $24.69
Upside: +33.66%
Neurocrine Biosciences
Jul 10, 2025
Initiates: Buy
Price Target: $182
Current: $155.51
Upside: +17.03%
CG Oncology
May 14, 2024
Upgrades: Buy
Price Target: $43 → $50
Current: $43.30
Upside: +15.47%
Immunovant
Mar 13, 2024
Initiates: Buy
Price Target: $50
Current: $22.84
Upside: +118.91%